Neuroimaging the Effectiveness of Substance Use Disorder Treatments (Journal of Neuroimmune Pharmacology, 2016)
Autoren: Elizabeth A. Cabrera, Corinde E. Wiers, Elsa Lindgren, Gregg Miller, Nora D. Volkow & Gene-Jack Wang
(pp, 21.07.2016)
Struktur des Inhalts
Abstract im englischen Original
Neuroimaging techniques to measure the function and biochemistry of the human brain such as positron emission tomography (PET), proton magnetic resonance spectroscopy (1H MRS), and functional magnetic resonance imaging (fMRI), are powerful tools for assessing neurobiological mechanisms underlying the response to treatments in substance use disorders. Here, we review the neuroimaging literature on pharmacological and behavioral treatment in substance use disorder. We focus on neural effects of medications that reduce craving (e.g., naltrexone, bupropion hydrochloride, baclofen, methadone, varenicline) and that improve cognitive control (e.g., modafinil, N-acetylcysteine), of behavioral treatments for substance use disorders (e.g., cognitive bias modification training, virtual reality, motivational interventions) and neuromodulatory interventions such as neurofeedback and transcranial magnetic stimulation. A consistent finding for the effectiveness of therapeutic interventions identifies the improvement of executive control networks and the dampening of limbic activation, highlighting their values as targets for therapeutic interventions in substance use disorders.
Link zum englischen Abstract
Volltext auf Anfrage
